SARS-CoV-2 Persistence in Immunocompromised Patients Requiring Treatment With Convalescent Plasma: A Case Report.

Publication date: Feb 01, 2024

Severe acute respiratory syndrome-2 (SARS-CoV-2) infection in immunocompromised patients presents a challenge, as patients with such conditions may have severe courses. Identifying modalities to shorten the course or lessen the severity of infection could be potentially beneficial. A 76-year-old male with follicular lymphoma on rituximab and lenalidomide presented with COVID-19 pneumonia requiring intensive care unit (ICU) level care for persistent hypoxemia. He was treated with an extended course of remdesivir, as recommended by the Infectious Diseases service, but he maintained a persistently high viral load, necessitating a delay of his cancer treatment until he had recovered from his infection. On hospital day 31, he was given one dose of convalescent plasma with improvement in his SARS-CoV-2 viral load. He was able to be discharged and resumed cancer treatment soon thereafter. Convalescent plasma is a potential therapeutic option for immunocompromised patients with SARS-CoV-2 infection and should be considered early in the hospital course. Additionally, cycle threshold monitoring may be beneficial in certain scenarios: for instance to guide consideration of alternative therapies in patients with severe COVID-19 who have persistent symptoms and viremia while on guideline-directed therapy.

Concepts Keywords
Covid convalescent plasma
Day covid-19
Immunocompromised cycle threshold
Pneumonia follicular lymphoma
Severe immunosuppressed


Type Source Name
disease MESH Immunocompromised Patients
disease VO report
disease MESH Severe acute respiratory syndrome
disease MESH infection
disease MESH follicular lymphoma
drug DRUGBANK Rituximab
drug DRUGBANK Lenalidomide
disease MESH COVID-19
disease MESH pneumonia
disease MESH Infectious Diseases
disease MESH cancer
disease VO dose
pathway REACTOME SARS-CoV-2 Infection
disease MESH viremia

Original Article

(Visited 1 times, 1 visits today)